According to Douglas House, a new analysis has been released that shows patients with type 2 diabetes (T2D) that are treated with Johnson & Johnson (JNJ) unit Janssen Pharmaceuticals’ INVOKANA (canagliflozin) experienced significantly less risk of cardiovascular (CV) death or hospitalization for heart failure (HHF).
- Based on the data, what is the reduction of fatal heart failure?
- Where was the study published and where was it presented?
- Does the company have the permission to market it as a cardiovascular reduction drug?
- What effect do you think this will have on the stock price of (JNJ) and why?
House, D. (2017). Johnson & Johnson’s Invokana lowers risk of CV death or hospitalization in T2D. Seaking Alpha news blog, March 12 (Retrievable online at https://seekingalpha.com/news/3338393-johnson-and-johnsons-invokana-lowers-risk-cv-death-hospitalization-t2d?app=1&uprof=14&dr=1#email_link)